Lexagene Holdings Inc LXXGQ

Healthcare Medical Devices

Lexagene Holdings Inc. is a molecular diagnostics company engaged in researching, developing and commercializing automated genetic analyzer devices in clinical and life science industries. The Company is focused on developing molecular diagnostic systems for pathogen detection and genetic testing for other molecular markers for on-site rapid testing in veterinary diagnostics, and for use in open-access markets such as food and water safety, clinical research, agricultural testing and biodefense. The Company's MiQLab System is an automated, open-access molecular diagnostic system for pathogen detection, allowing users to test for multiple pathogens onsite, returning results in approximately 2 hours. Its MiQLab System is an automated, multiplexing polymerase chain reaction (PCR)-based system designed for syndromic testing in human clinical diagnostics and veterinary diagnostics, as well as food safety testing, and open-access custom testing markets.

GREY:LXXGQ - Post by User

Lexagene Holdings Inc > Ready for another day of complete BS?

<< Previous

Bullboard Posts

Next >>

Comment by Forestviewon Apr 14, 2021 9:25am

107 Views

Post# 32991690

RE:RE: Ready for another day of complete BS?

I also hope there's a bounce so you're able to exit this company, Letsdoit. Your comments are baseless and unsupported by any facts. And beyond annoying.

So, I hope the vet data they've released, which I'm sure you'll take issue with because that's what you do, is very promising, and speaks to a great opportunity. So, good luck letsdoit. Hope to never hear from you again.

MiQLab is sensitive enough to detect the vast majority of clinical infections caused by target organisms
~100% positive percent agreement with culture data on processed canine urine samples
~99% negative percent agreement with culture data on processed canine urine samples
~99% overall percent agreement with culture data on processed canine urine samples
Detected Staphylococcus in 21 of 23 (91%) specimens from skin infections in a correlation study
Detected the mecA gene in 8 of 9 (89%) specimens that contained methicillin resistant Staphylococcus
Quantitative data on par with culture (r2 ~0.95)